Britain to be the 'go-to place' for innovators and investors, says PM

21 November 2016
ukparliament-big

UK Prime Minister Theresa May today outlined the first steps in a modern, ambitious Industrial Strategy which will build on the UK’s strengths and address the long-term structural challenges which can hold British businesses back.

The PM announced a new active role that backs British business and should make Britain the global go-to place for scientists, innovators and tech investors. She said that the government will provide an additional £2 billion ($2.46 billion) investment per year for research and development by the end of this Parliament.

Speaking today at the annual conference of the Confederations of British Industry (CBI) at the Grosvenor House hotel, she also announced a review of the support for organizations undertaking research through the tax system, looking at the global competitiveness of the UK offer. She stressed her "aim" for the UK to maintain its status as having the lowest corporation tax rate in the G20 group of countries. That could mean matching US President-elect Donald Trump's pledge to cut the tax on big firms to just 15% - a move experts said would cost the Treasury £10 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical